Recursion Pharmaceuticals vs Elevance Health

Side-by-side comparison of AI visibility scores, market position, and capabilities

Elevance Health leads in AI visibility (92 vs 48)
Recursion Pharmaceuticals logo

Recursion Pharmaceuticals

ChallengerHealthcare Tech

AI Drug Discovery / Computational Biology

Public AI drug discovery platform (NASDAQ: RXRX). 5 clinical programs. Merged with Exscientia ($688M). 2025 rev $74.7M. $755M cash. Founded 2013, Salt Lake City.

AI VisibilityBeta
Overall Score
C48
Category Rank
#1 of 1
AI Consensus
49%
Trend
up
Per Platform
ChatGPT
39
Perplexity
58
Gemini
47

About

Recursion Pharmaceuticals (NASDAQ: RXRX) is a computational biology company industrializing drug discovery with AI, founded in 2013 in Salt Lake City, Utah. Built Recursion OS, a vertically integrated platform unifying biology, chemistry, and clinical development. Completed $688M all-stock Exscientia merger (November 2024). Market cap ~$1.62B.

Full profile
Elevance Health logo

Elevance Health

LeaderHealthcare Tech

Enterprise

Indianapolis BCBS managed care (NYSE: ELV) ~$175B FY2024 revenue; Anthem renamed 2022, BCBS exclusive in 14 states, Carelon health services, Medicaid/MA medical cost pressure competing with UnitedHealth and Cigna.

AI VisibilityBeta
Overall Score
A92
Category Rank
#194 of 290
AI Consensus
68%
Trend
down
Per Platform
ChatGPT
88
Perplexity
88
Gemini
88

About

Elevance Health, Inc. (formerly Anthem, Inc.) is an Indianapolis, Indiana-based managed care and health services company — publicly traded on the New York Stock Exchange (NYSE: ELV) as an S&P 500 Health Care component — providing health insurance plans under the Blue Cross Blue Shield brand in 14 states (Indiana, Georgia, California, Colorado, Connecticut, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin), Medicare Advantage, Medicaid managed care, and commercial employer-sponsored health plans through Carelon (pharmacy and behavioral health services — formerly IngenioRx) to approximately 47 million medical members through approximately 100,000 employees. In fiscal year 2024, Elevance Health reported revenues of approximately $175 billion (predominantly premium revenues from employer-sponsored and government-program health plan members), with operating income under pressure from medical cost increases in the Medicaid segment (post-COVID health utilization normalization causing medical costs to exceed Medicaid actuarial pricing expectations set during the pandemic period of reduced care utilization). CEO Gail Boudreaux has executed the company's transformation from Anthem to Elevance Health (rebranded June 2022) — reflecting the broadened value proposition beyond health insurance into health services: Carelon Services (behavioral health, pharmacy benefit management, utilization management, home health services for both Elevance and external health plan clients) represents the strategy of building a health services ecosystem that retains value within the Elevance enterprise rather than paying external PBMs, behavioral health managers, and care management vendors.

Full profile

AI Visibility Head-to-Head

48
Overall Score
92
#1
Category Rank
#194
49
AI Consensus
68
up
Trend
down
39
ChatGPT
88
58
Perplexity
88
47
Gemini
88
39
Claude
86
53
Grok
99

Key Details

Category
AI Drug Discovery / Computational Biology
Enterprise
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Recursion Pharmaceuticals
AI Drug Discovery / Computational Biology

Integrations

Both integrate with
Only Elevance Health
Recursion Pharmaceuticals is classified as company. Elevance Health is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.